Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin neutralization by recombinant platelet factor 4 and protamine

J H Levy1, J G Cormack, A Morales

  • 1Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.

Anesthesia and Analgesia
|July 1, 1995
PubMed
Summary

Platelet factor 4 (PF4) effectively reverses heparin anticoagulation during cardiac surgery. This finding suggests recombinant PF4 as a potential alternative to protamine, particularly for patients with protamine allergies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A rapid protocol for purification of total RNA for tissues collected from pigs at a slaughterhouse.

Genetics and molecular research : GMR·2011
Same author

Guidelines for the treatment of acute ischaemic stroke.

Neurologia (Barcelona, Spain)·2011
Same author

Analysing the effect of public health campaigns on reducing excess weight: a modelling approach for the Spanish Autonomous Region of the Community of Valencia.

Evaluation and program planning·2011
Same author

[Toward the appropriate use of teleradiology].

Radiologia·2011
Same author

Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type.

Neurologia (Barcelona, Spain)·2011
Same author

Emergence of ageing-related changes in insulin secretion by pancreatic islets of male rat offspring of mothers fed a low-protein diet.

The British journal of nutrition·2011

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Biochemistry

Background:

  • Protamine is the sole available agent for reversing heparin-induced anticoagulation.
  • Platelet factor 4 (PF4), a naturally occurring platelet protein, possesses heparin-neutralizing properties.
  • Investigating novel anticoagulation reversal agents is crucial for patient safety during cardiac procedures.

Purpose of the Study:

  • To evaluate the efficacy of recombinant Platelet factor 4 (PF4) in reversing heparin anticoagulation in blood samples from cardiac surgery.
  • To compare the reversal capabilities of PF4 with protamine using activated clotting time (ACT) and thromboelastography.

Main Methods:

  • Blood samples from 33 cardiac surgery patients were analyzed for activated clotting time (ACT) and heparin levels.

Related Experiment Videos

  • Recombinant PF4 and protamine were added to heparinized blood at various ratios to determine reversal efficacy.
  • Viscoelastic analysis using thromboelastography was performed to assess clot formation dynamics.

    • Main Results:

    • Recombinant PF4 demonstrated statistically significant reversal of heparin anticoagulation at ratios of 3:1 and 3.5:1 (PF4:heparin).
    • Protamine reversal was effective at ratios of 1:1, 1.5:1, and 2:1 (protamine:heparin).
    • No significant differences were observed in viscoelastic clot formation between PF4 and protamine reversal.

    Conclusions:

    • Recombinant PF4 effectively reverses heparin-induced anticoagulation post-cardiopulmonary bypass at a 3.0:1 ratio.
    • PF4 presents a promising alternative to protamine, especially for patients experiencing protamine allergies.
    • Further clinical studies are warranted to confirm PF4's safety and efficacy in vivo.